These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1241 related items for PubMed ID: 23344663

  • 1. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
    Simonin K, N'Diaye M, Lheureux S, Loussouarn C, Dutoit S, Briand M, Giffard F, Brotin E, Blanc-Fournier C, Poulain L.
    Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cafestol overcomes ABT-737 resistance in Mcl-1-overexpressed renal carcinoma Caki cells through downregulation of Mcl-1 expression and upregulation of Bim expression.
    Woo SM, Min KJ, Seo BR, Nam JO, Choi KS, Yoo YH, Kwon TK.
    Cell Death Dis; 2014 Nov 06; 5(11):e1514. PubMed ID: 25375379
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737.
    Hauck P, Chao BH, Litz J, Krystal GW.
    Mol Cancer Ther; 2009 Apr 06; 8(4):883-92. PubMed ID: 19372561
    [Abstract] [Full Text] [Related]

  • 8. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis.
    Miller LA, Goldstein NB, Johannes WU, Walton CH, Fujita M, Norris DA, Shellman YG.
    J Invest Dermatol; 2009 Apr 06; 129(4):964-71. PubMed ID: 18987671
    [Abstract] [Full Text] [Related]

  • 9. Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells.
    Mazumder S, Choudhary GS, Al-Harbi S, Almasan A.
    Cancer Res; 2012 Jun 15; 72(12):3069-79. PubMed ID: 22525702
    [Abstract] [Full Text] [Related]

  • 10. PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.
    Jebahi A, Villedieu M, Pétigny-Lechartier C, Brotin E, Louis MH, Abeilard E, Giffard F, Guercio M, Briand M, Gauduchon P, Lheureux S, Poulain L.
    Cancer Lett; 2014 Jun 28; 348(1-2):38-49. PubMed ID: 24650799
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway.
    Li R, Zang Y, Li C, Patel NS, Grandis JR, Johnson DE.
    Mol Pharmacol; 2009 May 28; 75(5):1231-9. PubMed ID: 19246337
    [Abstract] [Full Text] [Related]

  • 16. Clitocine induces apoptosis and enhances the lethality of ABT-737 in human colon cancer cells by disrupting the interaction of Mcl-1 and Bak.
    Sun JG, Xiang J, Zeng XL, Li X, Wu P, Fung KP, Liu FY.
    Cancer Lett; 2014 Dec 28; 355(2):253-63. PubMed ID: 25304383
    [Abstract] [Full Text] [Related]

  • 17. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
    Hikita H, Takehara T, Shimizu S, Kodama T, Shigekawa M, Iwase K, Hosui A, Miyagi T, Tatsumi T, Ishida H, Li W, Kanto T, Hiramatsu N, Hayashi N.
    Hepatology; 2010 Oct 28; 52(4):1310-21. PubMed ID: 20799354
    [Abstract] [Full Text] [Related]

  • 18. Ionizing radiation sensitizes breast cancer cells to Bcl-2 inhibitor, ABT-737, through regulating Mcl-1.
    Wu H, Schiff DS, Lin Y, Neboori HJ, Goyal S, Feng Z, Haffty BG.
    Radiat Res; 2014 Dec 28; 182(6):618-25. PubMed ID: 25409124
    [Abstract] [Full Text] [Related]

  • 19. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.
    Rooswinkel RW, van de Kooij B, Verheij M, Borst J.
    Cell Death Dis; 2012 Aug 09; 3(8):e366. PubMed ID: 22875003
    [Abstract] [Full Text] [Related]

  • 20. EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma.
    Nalluri S, Peirce SK, Tanos R, Abdella HA, Karmali D, Hogarty MD, Goldsmith KC.
    Cancer Biol Ther; 2015 Aug 09; 16(2):276-86. PubMed ID: 25756510
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 63.